Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to -$27.8 million.

  • Adma Biologics' Cash from Financing Activities fell 925.9% to -$27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.9 million, marking a year-over-year increase of 51.46%. This contributed to the annual value of -$58.3 million for FY2024, which is 4953.45% down from last year.
  • Latest data reveals that Adma Biologics reported Cash from Financing Activities of -$27.8 million as of Q3 2025, which was down 925.9% from $48000.0 recorded in Q2 2025.
  • Adma Biologics' Cash from Financing Activities' 5-year high stood at $62.7 million during Q4 2022, with a 5-year trough of -$39.0 million in Q4 2023.
  • Over the past 5 years, Adma Biologics' median Cash from Financing Activities value was -$319041.0 (recorded in 2022), while the average stood at $5.1 million.
  • In the last 5 years, Adma Biologics' Cash from Financing Activities surged by 101433022.43% in 2021 and then plummeted by 622187.5% in 2024.
  • Quarter analysis of 5 years shows Adma Biologics' Cash from Financing Activities stood at $53.8 million in 2021, then grew by 16.58% to $62.7 million in 2022, then tumbled by 162.15% to -$39.0 million in 2023, then increased by 20.44% to -$31.0 million in 2024, then grew by 10.32% to -$27.8 million in 2025.
  • Its last three reported values are -$27.8 million in Q3 2025, $48000.0 for Q2 2025, and -$7.1 million during Q1 2025.